InChI
1S/C19H19N7O6/c20-19-25-15-14(17(30)26-19)23-11(8-22-15)7-21-10-3-1-9(2-4-10)16(29)24-12(18(31)32)5-6-13(27)28/h1-4,8,12,21H,5-7H2,(H,24,29)(H,27,28)(H,31,32)(H3,20,22,25,26,30)/t12-/m0/s1
SMILES string
NC(N1)=NC(C2=C1N=CC(CNC3=CC=C(C(N[C@@H](CCC(O)=O)C(O)=O)=O)C=C3)=N2)=O
InChI key
OVBPIULPVIDEAO-LBPRGKRZSA-N
grade
pharmaceutical primary standard
API family
folic acid
manufacturer/tradename
USP
application(s)
pharmaceutical (small molecule)
format
neat
正在寻找类似产品? 访问 产品对比指南
General description
本产品按照发行药典的发行和规定提供。支持本产品的所有信息，包括安全数据表和任何产品信息传单，都是在发行药典的授权下开发和发布的。如需进一步信息和支持，请访问现行药典网站。
Application
叶酸 USP参考标准品，预期用途是USP规定的指定质量测试和检测。也用于USP各论，例如：
- 叶酸片
- 叶酸注射液
- 叶酸复合口服液
- 含有矿物质的油溶性和水溶性维生素 咀嚼凝胶
- 亚叶酸钙
- L-5-甲基四氢叶酸钙片
Analysis Note
这些产品仅供测试和化验使用。它们不适用于人类或动物，也不能用于诊断、治疗或治愈任何类型的疾病。
Other Notes
可能适用相应的销售限制。
存储类别
11 - Combustible Solids
flash_point_f
Not applicable
flash_point_c
Not applicable
Folic Acid Compounded Oral Solution
USP43-NF38: United States Pharmacopeia and National Formulary
United States Pharmacopeia, 42(5), 2027-2027 (2017)
Folic Acid assay
USP43-NF38: United States Pharmacopeia and National Formulary
United States Pharmacopeia, 48(3), 6689-6689 (2022)
Folic Acid
USP43-NF38: United States Pharmacopeia and National Formulary
United States Pharmacopeia, 29(2), 2026-2026 (2020)
Folic Acid Tablets
United States Pharmacopeia, 48(3), 2028-2028 (2022)
Myra A Carpenter et al.
Journal of the American Society of Nephrology : JASN, 25(7), 1554-1562 (2014-03-15)
The optimal BP level in kidney transplant recipients remains uncertain. This post hoc analysis of the Folic Acid for Vascular Outcome Reduction in Transplantation (FAVORIT) trial cohort assessed associations of BP with a pooled cardiovascular disease (CVD) outcome and with
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持